The value of propoxyphene hydrochloride (Darvon) for the treatment of hyperhidrosis in the spinal cord injured patient: an anecdotal experience and case reports.
Hyperhidrosis is a condition affecting the spinal cord injured (SCI) patient that often does not respond well to medical management. While the aetiology of hyperhidrosis in SCI patients is not completely understood, the standard form of treatment is aimed at interrupting the sympathetic cholinergic eccrine sweat glands. It has been our experience in treating this condition that many patients will have a significant decrease in hyperhidrosis using propoxyphene hydrochloride (Darvon) 65 mg once or twice per day. Two of these patients are presented. While the mechanism of action is purely speculative, there is evidence to support the concept that opioids may act as a weak ganglionic blocking agent. We have found that a trial of this medication for SCI patients suffering from hyperhidrosis may produce very gratifying results. Further investigation into the treatment of this condition with propoxyphene hydrochloride is indicated.
D000328:Adult; D011431:Dextropropoxyphene / Q000627:therapeutic use*; D006801:Humans; D006945:Hyperhidrosis / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D013119:Spinal Cord Injuries / Q000150:complications*
D011431:Dextropropoxyphene